CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias

Zaher I. Chakhachiro, Zhuang Zuo, Tariq N. Aladily, Hagop M. Kantarjian, Jorge E. Cortes, Khaled Alayed, Martin H. Nguyen, L. Jeffrey Medeiros, Carlos Bueso-Ramos

Research output: Contribution to journalArticle

Abstract

Objectives: To assess CD105 (endoglin) expression in 119 acute myeloid leukemia (AML) and 13 control cases using immunohistochemistry. Methods: CD105 expression was assessed retrospectively by using immunohistochemistry in bone marrow specimens. Results: CD105 was strongly and diffusely positive in all 9 (100%) AMLs with t(15;17)(q24.1;q21.2), 2 (100%) AMLs with t(8;21)(q22;q22), 1 (100%) AML with t(6;9)(p23;q34), 7 (28%) of 25 AMLs with myelodysplasia-related changes, 1 (33%) of 3 therapy-related AMLs, 3 (16%) of 19 AMLs unclassifiable, 1 (14%) of 7 AMLs with inv(16)(p13.1q22), and 5 (11%) of 45 AMLs not otherwise specified. Uninvolved bone marrow in these cases showed no CD105 expression by erythroid precursors, megakaryocytes, or endothelial or stromal cells. Two of 13 control bone marrow specimens showed partial CD105 positivity in myeloid cells. In 21 strongly CD105+ AML cases tested for the IDH2 mutation, 9 (42%) were mutated (P = .004). Conclusions: These data suggest that CD105 could be a therapeutic target in a subset of patients with AML.

Original languageEnglish (US)
Pages (from-to)370-378
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume140
Issue number3
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Bone Marrow
Immunohistochemistry
Megakaryocytes
Myeloid Cells
Stromal Cells
Endothelial Cells
Mutation
Endoglin
Therapeutics

Keywords

  • Acute myeloid leukemia
  • CD105
  • Endoglin
  • IDH2 mutation
  • Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Chakhachiro, Z. I., Zuo, Z., Aladily, T. N., Kantarjian, H. M., Cortes, J. E., Alayed, K., ... Bueso-Ramos, C. (2013). CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. American Journal of Clinical Pathology, 140(3), 370-378. https://doi.org/10.1309/AJCPG8XH7ZONAKXK

CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. / Chakhachiro, Zaher I.; Zuo, Zhuang; Aladily, Tariq N.; Kantarjian, Hagop M.; Cortes, Jorge E.; Alayed, Khaled; Nguyen, Martin H.; Medeiros, L. Jeffrey; Bueso-Ramos, Carlos.

In: American Journal of Clinical Pathology, Vol. 140, No. 3, 01.09.2013, p. 370-378.

Research output: Contribution to journalArticle

Chakhachiro, ZI, Zuo, Z, Aladily, TN, Kantarjian, HM, Cortes, JE, Alayed, K, Nguyen, MH, Medeiros, LJ & Bueso-Ramos, C 2013, 'CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias', American Journal of Clinical Pathology, vol. 140, no. 3, pp. 370-378. https://doi.org/10.1309/AJCPG8XH7ZONAKXK
Chakhachiro, Zaher I. ; Zuo, Zhuang ; Aladily, Tariq N. ; Kantarjian, Hagop M. ; Cortes, Jorge E. ; Alayed, Khaled ; Nguyen, Martin H. ; Medeiros, L. Jeffrey ; Bueso-Ramos, Carlos. / CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. In: American Journal of Clinical Pathology. 2013 ; Vol. 140, No. 3. pp. 370-378.
@article{b93eb1b5df1e44ffa994a4f3b5171a0d,
title = "CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias",
abstract = "Objectives: To assess CD105 (endoglin) expression in 119 acute myeloid leukemia (AML) and 13 control cases using immunohistochemistry. Methods: CD105 expression was assessed retrospectively by using immunohistochemistry in bone marrow specimens. Results: CD105 was strongly and diffusely positive in all 9 (100{\%}) AMLs with t(15;17)(q24.1;q21.2), 2 (100{\%}) AMLs with t(8;21)(q22;q22), 1 (100{\%}) AML with t(6;9)(p23;q34), 7 (28{\%}) of 25 AMLs with myelodysplasia-related changes, 1 (33{\%}) of 3 therapy-related AMLs, 3 (16{\%}) of 19 AMLs unclassifiable, 1 (14{\%}) of 7 AMLs with inv(16)(p13.1q22), and 5 (11{\%}) of 45 AMLs not otherwise specified. Uninvolved bone marrow in these cases showed no CD105 expression by erythroid precursors, megakaryocytes, or endothelial or stromal cells. Two of 13 control bone marrow specimens showed partial CD105 positivity in myeloid cells. In 21 strongly CD105+ AML cases tested for the IDH2 mutation, 9 (42{\%}) were mutated (P = .004). Conclusions: These data suggest that CD105 could be a therapeutic target in a subset of patients with AML.",
keywords = "Acute myeloid leukemia, CD105, Endoglin, IDH2 mutation, Immunohistochemistry",
author = "Chakhachiro, {Zaher I.} and Zhuang Zuo and Aladily, {Tariq N.} and Kantarjian, {Hagop M.} and Cortes, {Jorge E.} and Khaled Alayed and Nguyen, {Martin H.} and Medeiros, {L. Jeffrey} and Carlos Bueso-Ramos",
year = "2013",
month = "9",
day = "1",
doi = "10.1309/AJCPG8XH7ZONAKXK",
language = "English (US)",
volume = "140",
pages = "370--378",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias

AU - Chakhachiro, Zaher I.

AU - Zuo, Zhuang

AU - Aladily, Tariq N.

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge E.

AU - Alayed, Khaled

AU - Nguyen, Martin H.

AU - Medeiros, L. Jeffrey

AU - Bueso-Ramos, Carlos

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Objectives: To assess CD105 (endoglin) expression in 119 acute myeloid leukemia (AML) and 13 control cases using immunohistochemistry. Methods: CD105 expression was assessed retrospectively by using immunohistochemistry in bone marrow specimens. Results: CD105 was strongly and diffusely positive in all 9 (100%) AMLs with t(15;17)(q24.1;q21.2), 2 (100%) AMLs with t(8;21)(q22;q22), 1 (100%) AML with t(6;9)(p23;q34), 7 (28%) of 25 AMLs with myelodysplasia-related changes, 1 (33%) of 3 therapy-related AMLs, 3 (16%) of 19 AMLs unclassifiable, 1 (14%) of 7 AMLs with inv(16)(p13.1q22), and 5 (11%) of 45 AMLs not otherwise specified. Uninvolved bone marrow in these cases showed no CD105 expression by erythroid precursors, megakaryocytes, or endothelial or stromal cells. Two of 13 control bone marrow specimens showed partial CD105 positivity in myeloid cells. In 21 strongly CD105+ AML cases tested for the IDH2 mutation, 9 (42%) were mutated (P = .004). Conclusions: These data suggest that CD105 could be a therapeutic target in a subset of patients with AML.

AB - Objectives: To assess CD105 (endoglin) expression in 119 acute myeloid leukemia (AML) and 13 control cases using immunohistochemistry. Methods: CD105 expression was assessed retrospectively by using immunohistochemistry in bone marrow specimens. Results: CD105 was strongly and diffusely positive in all 9 (100%) AMLs with t(15;17)(q24.1;q21.2), 2 (100%) AMLs with t(8;21)(q22;q22), 1 (100%) AML with t(6;9)(p23;q34), 7 (28%) of 25 AMLs with myelodysplasia-related changes, 1 (33%) of 3 therapy-related AMLs, 3 (16%) of 19 AMLs unclassifiable, 1 (14%) of 7 AMLs with inv(16)(p13.1q22), and 5 (11%) of 45 AMLs not otherwise specified. Uninvolved bone marrow in these cases showed no CD105 expression by erythroid precursors, megakaryocytes, or endothelial or stromal cells. Two of 13 control bone marrow specimens showed partial CD105 positivity in myeloid cells. In 21 strongly CD105+ AML cases tested for the IDH2 mutation, 9 (42%) were mutated (P = .004). Conclusions: These data suggest that CD105 could be a therapeutic target in a subset of patients with AML.

KW - Acute myeloid leukemia

KW - CD105

KW - Endoglin

KW - IDH2 mutation

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=84882795736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882795736&partnerID=8YFLogxK

U2 - 10.1309/AJCPG8XH7ZONAKXK

DO - 10.1309/AJCPG8XH7ZONAKXK

M3 - Article

C2 - 23955456

AN - SCOPUS:84882795736

VL - 140

SP - 370

EP - 378

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -